The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD
Open accessAbstract
BACKGROUND: The integrin alphavbeta3 plays an important role in angiogenesis and tumor cell metastasis, and is currently being evaluated as a target for new therapeutic approaches. Several techniques are being studied to enable noninvasive determination of alphavbeta3 expression. We developed [(18)F]Galacto-RGD, a (18)F-labeled glycosylated alphavbeta3 antagonist, allowing monitoring of alphavbeta3 expression with positron emission tomography (PET). METHODS AND FINDINGS: Here we show by quantitative analysis of images resulting from a small-animal PET scanner that uptake of [(18)F]Galacto-RGD in the tumor correlates with alphavbeta3 expression subsequently determined by Western blot analyses. Moreover, using the A431 human squamous cell carcinoma model we demonstrate that this approach is sensitive enough to visualize alphavbeta3 expression resulting exclusively from the tumor vasculature. Most important, this study shows, that [(18)F]Galacto-RGD with PET enables noninvasive quantitative assessment of the alphavbeta3 expression pattern on tumor and endothelial cells in patients with malignant tumors. CONCLUSIONS: Molecular imaging with [(18)F]Galacto-RGD and PET can provide important information for planning and monitoring anti-angiogenic therapies targeting the alphavbeta3 integrins and can reveal the involvement and role of this integrin in metastatic and angiogenic processes in various diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Role of integrins in cell invasion and migration
Hood, J. D., & Cheresh, D. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc727 · Cited by 1,777
Takagi, J., Petre, B. M., Walz, T., & Springer, T. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00935-2 · Cited by 1,168
Tumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850
N -Methylated Cyclic RGD Peptides as Highly Active and Selective α V β 3 Integrin Antagonists
Dechantsreiter, M. A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S. L., & Kessler, H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm970832g · Cited by 838
Self-citationAntiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
Brooks, P. C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Cheresh, D. A., & Spiro, R. C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45436-1 · Cited by 565
Haubner, R., Wester, H. J., Weber, W., Mang, C., Ziegler, S. I., Goodman, S. L., Senekowitsch–Schmidtke, R., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 563
Self-citationAumailley, M., Gurrath, M., Müller, G., Calvete, J., Timpl, R., & Kessler, H. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)81101-d · Cited by 551
Self-citationRadiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner, R., Wester, H., Reuning, U., Senekowitsch–Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., & Schwaiger, M. (1999) · PubMed · Cited by 413
Self-citationReproducibility of metabolic measurements in malignant tumors using FDG PET.
Weber, W., Ziegler, S. I., Thödtmann, R., Hanauske, A.-R., & Schwaiger, M. (1999) · PubMed · Cited by 388
Self-citationHaubner, R., Wester, H. J., Burkhart, F., Senekowitsch–Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 381
Self-citationInvolvement of integrin alpha V gene expression in human melanoma tumorigenicity.
Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., & Cheresh, D. A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115811 · Cited by 378
Winter, P. M., Caruthers, S. D., Kassner, A., Harris, T. D., Chinen, L. K., Allen, J. S., Lacy, E. K., Zhang, H., Robertson, J. D., Wickline, S. A., et al. (2003) · PubMed · Cited by 371
Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D., & Cheresh, D. A. (2000) · PubMed · Cited by 369
Integrin adhesion receptors in tumor metastasis
Felding-Habermann, B. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022983000355 · Cited by 287
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.
Gasparini, G., Brooks, P. C., Biganzoli, E. M., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R., & Cheresh, D. A. (1998) · PubMed · Cited by 280
Magnetic resonance contrast enhancement of neovasculature with ?v?3-targeted nanoparticles
Anderson, S. A., Rader, R. K., Westlin, W. F., Null, C., Jackson, D., Lanza, G. M., Wickline, S. A., & Kotyk, J. J. (2000) · Magnetic Resonance in Medicine · doi:10.1002/1522-2594(200009)44:3<433::aid-mrm14>3.0.co;2-9 · Cited by 271
Thumshirn, G., Hersel, U., Goodman, S. L., & Kessler, H. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200204304 · Cited by 269
Self-citationChen, X. S., Hou, Y., Tohme, M. S., Park, R. J.-H., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J. R., Laug, W. E., & Conti, P. S. (2004) · PubMed · Cited by 254
Vartanian, R. K., & Weidner, N. (1994) · PubMed · Cited by 232
Poethko, T., Schottelius, M., Thumshirn, G., Hersel, U., Herz, M., Henriksen, G., Kessler, H., Schwaiger, M., & Wester, H. (2004) · PubMed · Cited by 227
Self-citationMicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptides
CHEN, X., LIU, S., HOU, Y., TOHME, M., PARK, R., BADING, J., & CONTI, P. (2004) · Molecular Imaging & Biology · doi:10.1016/j.mibio.2004.06.004 · Cited by 212
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
Chen, X., Park, R., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2003.07.003 · Cited by 203
Taga, T., Suzuki, A., Gonzalez‐Gomez, I., Gilles, F. H., Stins, M., Shimada, H., Barsky, L., Weinberg, K. I., & Laug, W. E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10265 · Cited by 198
Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic Therapies
Haubner, R., & Wester, H.-J. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384745 · Cited by 198
Self-citationNew paradigms for the treatment of cancer: The role of anti-angiogenesis agents
(2000) · Advances in Cancer Research · doi:10.1016/s0065-230x(00)79001-4 · Cited by 193
Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting
Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Radjopadhye, M., Corstens, F. H. M., & Boerman, O. C. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497802320970244 · Cited by 174
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 170
Ziegler, S. I., Pichler, B. J., Boening, G., Rafecas, M., Pimpl, W., Eckart Lorenz, G., Schmitz, N., & Schwaiger, M. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590000438 · Cited by 165
Self-citationMicro-PET Imaging of αvβ3-Integrin Expression with 18F-Labeled Dimeric RGD Peptide
Chen, X., Tohme, M., Park, R., Hou, Y., Bading, J. R., & Conti, P. S. (2004) · Molecular Imaging · doi:10.1162/1535350041464892 · Cited by 159
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide
Chen, X. S., Park, R. J.-H., Hou, Y., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M. S., Bading, J. R., Laug, W. E., & Conti, P. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1452-2 · Cited by 158
Overview of angiogenesis: Biologic implications for antiangiogenic therapy
Ellis, L. M., Liu, W., Ahmad, S. A., Fan, F., Jung, Y. D., Shaheen, R. M., & Reinmuth, N. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90287-8 · Cited by 135
Tumor angiogenesis as a therapeutic target
Matter, A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01939-0 · Cited by 119
Improvement of Pharmacokinetics of Radioiodinated Tyr3-Octreotide by Conjugation with Carbohydrates
Schottelius, M., Wester, H., Reubi, J. C., Senekowitsch–Schmidtke, R., & Schwaiger, M. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0200069 · Cited by 102
Self-citationRaguse, J.-D., Gath, H. J., Bier, J., Riess, H. B., & Oettle, H. (2003) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.003 · Cited by 87
Haubner, R., Bruchertseifer, F., Bock, M. J., Kessler, H., Schwaiger, M., & Wester, H. J. (2004) · PubMed · doi:10.1267/nukl04010026 · Cited by 47
Self-citationSmith, J. W. (2003) · PubMed · Cited by 43
Teti, A. M., Migliaccio, S., & Baron, R. (2002) · Calcified Tissue International · doi:10.1007/s00223-001-2071-1 · Cited by 37
Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status
Wester, H., Schottelius, M., Poethko, T., Bruus-Jensen, K., & Schwaiger, M. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497804323072011 · Cited by 37
Self-citationRecent developments in antiangiogenic therapy
Dredge, K. S., Dalgleish, A. G., & Marriott, J. B. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.8.953 · Cited by 17
Cited by
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
Metadata
- Authors
- Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.-F., Goebel, M., Hein, R., Wester, H.-J., Kessler, H., & Schwaiger, M.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2005-03-29
- Volume
- 2
- Issue
- 3
- Pages
- e70
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2032338421
- Cited by
- 489
- References
- 46
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.